The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study - 01/12/17
, Karn Wijarnpreecha c , Patompong Ungprasert d, e Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 2 |
| Video | 0 |
| Altro | 0 |
Summary |
Background |
Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder worldwide. Several noninvasive diagnostic scoring systems have been developed to determine the severity of liver fibrosis and to predict long-term outcome of patients with NAFLD in lieu of liver biopsy. We conducted this systematic review and meta-analysis to investigate the role of NAFLD fibrosis score (NFS) for prediction of mortality from NAFLD.
Methods |
MEDLINE and EMBASE databases were searched through October 2016 for studies that investigated the association between high NFS and mortality. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated using a random-effects model, generic inverse variance method. The between-study heterogeneity of effect-size was quantified using the Q statistic and I2.
Results |
A total of five cohort studies with 5033 NAFLD patients were identified. High NFS (score of greater than 0.675) was significantly associated with increased mortality with the pooled RR of 4.54 (95%CI: 1.85–11.17). The statistical heterogeneity was high with I2 of 88% (Pheterogeneity<0.01).
Conclusions |
High NFS is associated with increased risk of mortality among patients with NAFLD. This scoring system may be considered as an alternative to liver biopsy for prediction of mortality outcome.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Mortality, Meta-analysis, Nonalcoholic fatty liver disease, Nonalcoholic fatty liver disease fibrosis score, Prognosis
Mappa
Vol 41 - N° 6
P. 629-634 - Dicembre 2017 Ritorno al numero
Articolo precedente
- Managing pre-symptomatic Wilson disease in genetic era – More questions than answers
- Nedim Hadži?, Maesha Deheragoda, Anil Dhawan
- Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy
- Jie Li, Xizhen Sun, Jianting Fang, Chuanxi Wang, Guoqing Han, Wanhua Ren
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?